MMRF Research: Targeting ERAD and UPR in myeloma
From the Summer 2005 Newsletter of the Multiple Myeloma Research Foundation.
Allan M. Weissman, MD, Center for Cancer Research, NCI-Frederick
Project Title: Targeting ERAD and UPR in multiple myeloma
Abstract: Dr. Weissman's research will investigate endoplasmaic reticulum-associated degradation (ERAD), a process by which myeloma cells destroy excess antibodies and proteins in order to survive. By blocking this process, Dr. Weissman believes myeloma cell death can occur, as has happened in studies of mice. He will use this funding to apply these findings to human myeloma as a step toward new therapeutics for treatment.
Allan M. Weissman, MD, Center for Cancer Research, NCI-Frederick
Project Title: Targeting ERAD and UPR in multiple myeloma
Abstract: Dr. Weissman's research will investigate endoplasmaic reticulum-associated degradation (ERAD), a process by which myeloma cells destroy excess antibodies and proteins in order to survive. By blocking this process, Dr. Weissman believes myeloma cell death can occur, as has happened in studies of mice. He will use this funding to apply these findings to human myeloma as a step toward new therapeutics for treatment.
posted by gwg at 1:23 PM
0 Comments:
Post a Comment
<< Home